Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | FNTA | P49354 | 2/20 | 0.39 |
| ▸ | FNTB | P49356 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | MMP12 | P39900 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9614381 | 0.97 | KDM4E (0.46) | KDM4ETHRBRECQLNFKB1MAPT | |
| Butane SCHEMBL5183779 | 0.89 | KDM4E (0.46) | KDM4ETHRBRECQLNFKB1MAPT | |
| SCHEMBL3869217 | 0.88 | KDM4E (0.44) | KDM4ETHRBRECQLNFKB1MAPT | |
| SCHEMBL9336407 | 0.88 | KDM4E (0.44) | KDM4ETHRBRECQLNFKB1MAPT | |
| SCHEMBL24938422 | 0.84 | KDM4E (0.41) | KDM4ETHRBRECQLNFKB1MAPT | |
| SCHEMBL2165150 | 0.84 | ALOX15 (0.41) | KDM4ETHRBRECQLNFKB1MAPT | |
| SCHEMBL6986221 | 0.82 | SMN1; SMN2 (0.40) | KDM4ETHRBRECQLNFKB1MAPT | |
| SCHEMBL17483032 | 0.82 | SMN1; SMN2 (0.40) | KDM4ETHRBRECQLNFKB1MAPT | |
| SCHEMBL27842807 | 0.80 | MAPT (0.43) | KDM4ETHRBRECQLNFKB1MAPT | |
| SCHEMBL6118521 | 0.80 | MAPT (0.43) | KDM4ETHRBRECQLNFKB1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118685774-A | Cu-MTD etching solution for liquid crystal display panel and preparation method thereof | 四川江化微电子材料有限公司 | 2024-09-24 | — | — | CN | claimed |
| CN-108383744-A | A kind of preparation method of 2,6- dimethyl-tyrosine | 浙江工业大学 | 2018-08-10 | — | — | CN | claimed |
| CN-105712901-B | A kind of synthetic method of the nonenoic acid dicyclohexyl amine salt of 2 amino of optical activity intermediate N tertbutyloxycarbonyls 8 | 成都柏睿泰生物科技有限公司 | 2017-07-14 | — | — | CN | claimed |
| CN-106606423-A | Chitosan water-soluble combination agent and application thereof | 李建明 | 2017-05-03 | — | — | CN | claimed |
| CN-105712901-A | Method for synthesizing optically active intermediate N-tert-butoxycarbonyl-2-amino-8-nonenoic dicyclohexylamine salt | 成都柏睿泰生物科技有限公司 | 2016-06-29 | — | — | CN | claimed |
| US-20160031800-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | VISTAGEN THERAPEUTICS, INC. | 2016-02-04 | — | — | US | claimed |
| EP-2970080-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | Vistagen Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014152835-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | VISTAGEN THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | claimed |
| EP-0663899-B1 | SUBSTITUTED KYNURENINES, A PROCESS FOR THEIR PREPARATION, AND USE AS MEDICAMENTS | UNIV MARYLAND (US) | 1999-06-30 | — | — | EP | claimed |
| EP-0919538-A1 | Substituted kynurenines, a process for their preparation, and use as medicaments | THE UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1999-06-02 | — | — | EP | claimed |
| EP-0663899-A4 | SUBSTITUTED KYNURENINES, A PROCESS FOR THEIR PREPARATION, AND USE AS MEDICAMENTS. | UNIV MARYLAND (US) | 1996-01-17 | — | — | EP | claimed |
| EP-0663899-A1 | SUBSTITUTED KYNURENINES, A PROCESS FOR THEIR PREPARATION, AND USE AS MEDICAMENTS | THE UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1995-07-26 | — | — | EP | claimed |
| WO-1995004714-A1 | SUBSTITUTED KYNURENINES, A PROCESS FOR THEIR PREPARATION, AND USE AS MEDICAMENTS | UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1995-02-16 | — | — | WO | claimed |
| EP-0231709-B1 | PHENYL NAPHTHYRIDINES, WITH A FUNCTIONAL GROUP IN POSITION 3, PROCESS FOR THEIR PREPARATION, MEDICAMENTS CONTAINING THEM, ESPECIALLY AS ANTI-ULCERS | LABORATOIRES UPSA (FR) | 1992-07-22 | — | — | EP | claimed |
| EP-0242709-A2 | Antagonists of specific excitatory amino acid neurotransmitter receptors | NOVA PHARMACEUTICAL CORPORATION (US) | 1987-10-28 | — | — | EP | claimed |
| EP-0003335-B1 | PROCESS FOR PREPARING AMINOMALONIC ACID DINITRILE TOSYLAT OR ACETYLAMINOMALONIC ACID DINITRIL | LONZA AG (CH) | 1981-07-01 | — | — | EP | claimed |
| US-12612421-B2 | Method for producing 4-borono-L-phenylalanine and intermediate thereof | STELLA PHARMA CORPORATION (JP) | 2026-04-28 | — | — | US | disclosed |
| CN-118685774-B | Cu-MTD etching solution for liquid crystal display panel and preparation method thereof | 四川江化微电子材料有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-4084057-A | Process for the production of 4-acylamido-4, 4-dicarbalkoxy-butanalphenylhydrazone | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1978-04-11 | — | — | US | disclosed |
| US-4073795-A | Synthesis of tryptophans | HOFFMANN-LA ROCHE INC. (US) | 1978-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612421-B2 | Method for producing 4-borono-L-phenylalanine and intermediate thereof | BCAT2, BCAT1, CLIC4 | KDM4E 3078/4885THRB 106/4885RECQL 4114/4885 |
| US-20160031800-A1 | SYNTHESIS OF CHIRAL KYNURENINE COMPOUNDS AND INTERMEDIATES | KYNU, KMO, AADAT | KDM4E 749/4885THRB 2839/4885RECQL 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.